Citius Historical Income Statement
| CTOR Stock | 0.92 0.02 2.13% |
Historical analysis of Citius Oncology, income statement accounts such as Selling General Administrative of 5.1 M, Total Revenue of 0.0 or Research Development of 4.2 M can show how well Citius Oncology, performed in making a profits. Evaluating Citius Oncology, income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Citius Oncology,'s future profits or losses.
Citius Oncology, Net Income |
|
Citius |
About Citius Income Statement Analysis
Citius Oncology, Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Citius Oncology, shareholders. The income statement also shows Citius investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Citius Oncology, Income Statement Chart
Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Citius Oncology,'s income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Citius Oncology, current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Oncology,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Citius Stock, please use our How to Invest in Citius Oncology, guide.
| 2010 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 4.9M | 12.1M | 13.9M | 9.3M | Research Development | 3.4M | 4.2M | 4.9M | 4.2M |
Citius Oncology, income statement Correlations
Click cells to compare fundamentals
Citius Oncology, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with Citius Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.64 | VCYT | Veracyte | PairCorr |
| 0.59 | DRUG | Bright Minds Biosciences Trending | PairCorr |
| 0.55 | DMAC | DiaMedica Therapeutics Trending | PairCorr |
| 0.51 | VERA | Vera Therapeutics | PairCorr |
The ability to find closely correlated positions to Citius Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology, to buy it.
The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.